A
Alveron Pharma
Alveron Pharma is developing a unique coagulation platform technology with the world's first cyclodextrin-based anticoagulant reversal drug
About Alveron Pharma
Alveron Pharma is pioneering a unique coagulation platform technology, focusing on the development of the world's first cyclodextrin-based anticoagulant reversal drug. The company's proprietary cyclodextrin-based compounds accelerate coagulation without initiating it, making them effective systemic anti-bleeding agents. Alveron's lead program aims to create a universal anticoagulant reversal agent, addressing a critical need in medical treatments where bleeding risks are prevalent. The company primarily serves healthcare providers and pharmaceutical companies, operating within the medical and biotech markets. Alveron Pharma's business model revolves around the research, development, and eventual commercialization of its proprietary compounds. Revenue is generated through partnerships, licensing agreements, and future sales of its developed drugs.
Source: Dealroom company dataNews
Open roles
Alveron Pharma in the Nijmegen ecosystem
The Alveron Pharma office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed5 investors entered at this stage
- WVWaterman Ventures
Thuja Capital
Oost NL - Eastern Netherlands Regional Development Agency
Broadview Ventures
Sanquin
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Alveron Pharma on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Alveron Pharma on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

